MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It has been studied as a metabolic regulator with roles in insulin sensitivity, exercise capacity, and aging-related metabolic decline. Most of the data sits in animal models, with limited human evidence.
Like BPC-157 and TB-500, MOTS-c has become a popular research peptide in the longevity and biohacking community. The PCAC and FDA's Section 503A bulks list categorization is in progress; state medical board enforcement actions have included it. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed MOTS-c among the 19 injectable peptides at issue.
Clinical evidence in humans is preliminary. Stories here cover regulatory action and any progress toward registered trials.
The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its first procedural cutoff Thursday July 9, 2026 at 11:59 PM ET. Comments submitted by this deadline will be formally provided to PCAC members ahead of the July 23-24 meeting. Written submissions after July 9 remain on the record but reach members after their initial review preparation. The docket's absolute hard deadline for all written comment submissions is July 22, 2026 at 11:59 PM ET (one day before the meeting opens). Compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer advocacy voices (Public Citizen), academic researchers (UC Davis's Paul Knoepfler), and individual physicians have filed comments across both the pro-approval and pro-restriction sides of the panel decision. The FDA career-staff briefing documents (released June 29-30) concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity concerns, heavy-metal and microbial contamination in compounded product samples, mislabeled contents, and thin 503A historical use. The July 9 threshold is the operational moment at which panelists get their reading pile; the record they use to deliberate the July 23-24 vote is set today.
FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 closed at the end of business Tuesday June 30, 2026. Individuals or organizations who wanted to give a formal oral presentation at the public-comment portion of the meeting had to notify FDA by today with a brief description of the evidence or arguments to be presented, names and addresses of participants, in-person versus virtual preference, and a requested time allotment. Written comments to docket FDA-2025-N-6895 at regulations.gov remain open through July 9, 2026 for formal provision to PCAC members ahead of the meeting; the hard deadline for all written comments is July 22, 2026 at 11:59 PM ET. The two-day meeting at FDA's White Oak campus in Silver Spring, Maryland (with virtual attendance option) reviews seven peptides for 503A bulks list eligibility: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Oral-testimony filers will face the FDA career-staff briefing documents released this week concluding the evidence is insufficient on all seven substances.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.